Low within‐ and between‐day variability in exposure to new insulin glargine 300 U/ml
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aims: To characterize the variability in exposure and metabolic effect of insulin glargine 300 U/ml ( Gla‐300 ) at steady state in people with type 1 diabetes ( T1DM ). Methods: A total of 50 participants with T1DM underwent two 24‐h euglycaemic clamps in steady‐state conditions after six once‐daily administrations of 0.4 U/kg Gla‐300 in a double‐blind, randomized, two‐treatment, two‐period, crossover clamp study. Participants were randomized to receive Gla‐300 as a standard cartridge formulation in the first treatment period, and as a formulation with enhanced stability through polysorbate‐20 addition in the second treatment period, or vice versa. This design allowed the assessment of bioequivalence between formulations and, subsequently, within‐ and between‐day variability. Results: The cumulative exposure and effect of Gla‐300 developed linearly over 24 h, and were evenly distributed across 6‐ and 12‐h intervals. Diurnal fluctuation in exposure (within‐day variability) was low; the peak‐to‐trough ratio of insulin concentration profiles was <2, and both the swing and peak‐to‐trough fluctuation were <1. Day‐to‐day reproducibility of exposure was high: the between‐day within‐subject coefficients of variation for total systemic exposure (area under the serum insulin glargine concentration time curve from time 0 to 24 h after dosing) and maximum insulin concentration were 17.4% [95% confidence interval ( CI ) 15–21] and 33.4% (95% CI 28–41), respectively. Reproducibility of the metabolic effect was lower than that of exposure. Conclusions: Gla‐300 provides predictable, evenly distributed 24‐h coverage as a result of low fluctuation and high reproducibility in insulin exposure, and appears suitable for effective basal insulin use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) · Diabetes Care · doi:10.2337/diacare.26.2007.s5 · Cited by 2,689
Becker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407
Self-citationHeise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397 · cited 14×
“This observation is confirmed by replicate studies in T1DM with rapid-acting insulin analogue products at 0.3 U/kg, presenting a PK variability of 7% at a PD variability of 17% (data not shown).”
BackgroundInfluentialUltra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes
Heise, T., Nosek, L., Bøttcher, S. G., Hastrup, H., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01638.x · Cited by 331 · cited 2×
“[11] reported an almost equal distribution (12-h fractions) of insulin degludec activity over 24 h at steady state, irrespective of dose (GIR-AUC0–12/GIR-AUC0–24 of 0.”
BackgroundResultYki-Järvinen, H., Bergenstal, R., Ziemen, M., Wardecki, M., Muehlen-Bartmer, I., Boelle, E., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-0990 · Cited by 274
Korsatko, S., Deller, S., Koehler, G., Mader, J. K., Neubauer, K., Adrian, C. L., Thomsen, H., Haahr, H., & Pieber, T. R. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0096-7 · Cited by 89 · cited 15×
“This observation is confirmed by replicate studies in T1DM with rapid-acting insulin analogue products at 0.3 U/kg, presenting a PK variability of 7% at a PD variability of 17% (data not shown).”
BackgroundResultInfluentialArnolds, S., Kuglin, B., Kapitza, C., & Heise, T. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02470.x · Cited by 69
Self-citationHompesch, M., Morrow, L., Watkins, E., Roepstorff, C., Thomsen, H. F., & Haahr, H. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.12.014 · Cited by 20
Cited by
Insulin analogues in type 1 diabetes mellitus: Getting better all the time
Mathieu, C., Gillard, P., & Benhalima, K. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.39 · Cited by 248
Treatment strategies against diabetes: Success so far and challenges ahead.
Khursheed, R., Singh, S. K., Wadhwa, S., Kapoor, B., Gulati, M., Kumar, R., Ramanunny, A. K., Awasthi, A., & Dua, K. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172625 · Cited by 239
Famulla, S., Hövelmann, U., Fischer, A., Coester, H.-V., Hermanski, L., Kaltheuner, M., Kaltheuner, L., Heinemann, L., Heise, T., & Hirsch, L. (2016) · Diabetes Care · doi:10.2337/dc16-0610 · Cited by 173
Visentin, R., Schiavon, M., Giegerich, C., Klabunde, T., Man, C. D., & Cobelli, C. (2019) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2019.2897851 · Cited by 22
“respectively, as reported in [22].”
Cheng, A. Y. Y., Wong, J., Freemantle, N., Acharya, S. H., & Ekinci, E. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00925-8 · Cited by 20
the RESTORE-1 Study Group, Laviola, L., Porcellati, F., Bruttomesso, D., Larosa, M., Rossi, M. C., & Nicolucci, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00982-z · Cited by 16
Understanding concentrated insulins: a systematic review of randomized controlled trials
Ovalle, F., Segal, A. R., Anderson, J. E., Cohen, M. R., Morwick, T. M., & Jackson, J. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1409426 · Cited by 16
Management of severe insulin resistance in patients with type 1 diabetes
Schechter, R., & Reutrakul, S. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0641-2 · Cited by 15
Battelino, T., Edelman, S. V., Nishimura, R., & Bergenstal, R. M. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0180 · Cited by 13
Roussel, R., d'Emden, M. C., Fisher, M., Ampudia‐Blasco, F. J., Stella, P., Bizet, F., Cali, A. M. G., & Wysham, C. H. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13071 · Cited by 6
“longed pharmacokinetic/pharmacodynamic profile compared with Gla-100, with low variability and high reproducibility, resulting in more predictable and evenly distributed glucose-lowering activity beyond 24 hours.(9,10) This extended and more stable coverage may enable more people currently administering multiple daily…”
Metadata
- Authors
- Becker, R. H. A., Nowotny, I., Teichert, L., Bergmann, K., & Kapitza, C.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2015-01-07
- Volume
- 17
- Issue
- 3
- Pages
- 261-267
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2089128745
- Cited by
- 125
- References
- 8
- FWCI
- 12.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.